[{"id":"6df094c2-9111-440a-b8d9-ef9270259908","acronym":"","url":"https://clinicaltrials.gov/study/NCT03961971","created_at":"2021-07-05T17:22:45.637Z","updated_at":"2025-02-25T15:43:33.280Z","phase":"Phase 1","brief_title":"Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM","source_id_and_acronym":"NCT03961971","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • sabatolimab (MBG453)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-01-03"},{"id":"8c5b3516-4a7c-4205-ad40-e97eec56da64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03940352","created_at":"2021-01-18T19:24:11.865Z","updated_at":"2024-07-02T16:34:27.521Z","phase":"Phase 1","brief_title":"HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03940352","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • sabatolimab (MBG453) • siremadlin (HDM201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 06/14/2024","primary_completion_date":" 06/14/2024","study_txt":" Completion: 06/14/2024","study_completion_date":" 06/14/2024","last_update_posted":"2024-06-11"}]